Quick Facts

• May support the treatment of infections in the digestive system.
• Intended to help manage conditions like diarrhea and dysentery caused by certain pathogens.
• Used for combating various bacterial and parasitic infections in adults.

Fynal-OZ is a medication approved for use in adult patients to address specific bacterial and parasitic infections. It is indicated to manage infections within the gastrointestinal system, including instances of diarrhea and dysentery that may be associated with sensitive bacteria and parasites.

This medication is used to help stop the progression of these infections, which can be connected to discomfort and changes in bowel function. Additionally, Fynal-OZ is intended to help manage bacterial infections in other sites, such as certain respiratory, urinary tract, and gynecological infections, when caused by susceptible organisms. The primary goal of the treatment is to manage the infection to support patient comfort and a return to baseline function. Healthcare professionals rely on clinical guidelines for therapeutic use when prescribing this type of antimicrobial combination therapy. Completing the full course of treatment is generally recommended to achieve the intended therapeutic outcome.

Eligibility Map: Official Regulatory Information

The eligibility profile for Fynal-OZ (Levofloxacin + Ornidazole) is strictly defined by regulatory authorities and is largely restricted to Adult Patients (ge 18 years) who do not have documented non-eligibility conditions.

Condition-Specific Eligibility Rules

Use of Fynal-OZ is designated as Conditional or requires Caution for several populations, including:

• Renal Impairment: Requires conditional use, where dose adjustment is officially mandated based on the degree of kidney function impairment.
• Severe Hepatic Impairment: Use requires conditional use and official modification of the dosing interval.
• Older Adults (ge 60 years): Eligible with Caution due to an increased regulatory warning for the risk of tendinopathy (tendon rupture).
• Cardiovascular Conditions: Avoidance is advised in patients with known QT interval prolongation or uncorrected hypokalemia due to cardiac risk.
• Other Restrictions: Caution is required for patients with a history of CNS disorders or those who are organ transplant recipients.

Interactions with other medicines and products

Official regulatory documents define specific interaction constraints for Fynal-OZ, primarily driven by its active ingredients, Levofloxacin and Ornidazole. Co-administration is contraindicated with certain medicines, including Pimozide and Dronedarone, due to the additive risk of prolonging the QT interval, a recognized pharmacodynamic effect. This restriction applies to all products known to significantly affect cardiac rhythm.

A mandatory timing rule exists for products containing multivalent cations, such as certain antacids or supplements with iron or zinc. These products must be administered at least 2 hours apart from Fynal-OZ tablets to prevent chelation, which officially reduces the absorption and exposure of the Levofloxacin component.

Warfarin's effects are officially enhanced when co-administered, requiring monitoring of blood metrics. Pharmacodynamic cautions also apply to concurrent use with NSAIDs, which can lower the seizure threshold, and with corticosteroids, which formally increase the risk of tendon disorders. This increased tendon risk is noted to be greater in geriatric patients.

Finally, consumption of alcohol (ethanol) is restricted during treatment and for a mandatory 3 days after treatment discontinuation due to the risk of a documented Disulfiram-like reaction.

The action of Fynal-OZ is based on a dual-pathway antimicrobial strategy that targets two distinct classes of pathogens simultaneously, resulting in the comprehensive termination of microbial load across multiple pathogen types.

Levofloxacin's core mechanism involves the targeted inhibition of bacterial DNA Gyrase and Topoisomerase IV, two essential enzymes in aerobic cells. The drug binds to the DNA-enzyme complex, stabilizing the temporary strand breaks and initiating a lethal cascade of DNA double-strand breaks. This results in the cessation of bacterial proliferation and subsequent depletion of the aerobic microbial population.

Ornidazole functions as a prodrug that is activated by specialized Nitroreductase enzymes found within susceptible anaerobic bacteria and protozoa. This enzymatic reduction generates cytotoxic free radicals which cause immediate and irreversible damage to the pathogen's genetic material. This chemical destruction results in the targeted depletion of the anaerobic and protozoal populations.

The combination provides additive mechanistic coverage by encompassing the molecular pathways of both aerobic and anaerobic/protozoal organisms through fundamentally different modes of action (enzyme inhibition versus free-radical generation).

Fynal-OZ is an antimicrobial combination drug administered exclusively through the oral route as a film-coated tablet. This fixed-dose combination contains Levofloxacin (250 mg) and Ornidazole (500 mg) per unit dose. The general usage principle defines a Twice Daily (BID) schedule, which is derived from the dosing requirements for the Ornidazole component and typical antimicrobial combinations.

Official Administration Conditions

The established protocol for Fynal-OZ is a short-term course of treatment, typically lasting between 5 and 10 days. Administration should be performed by ingesting the tablet with or immediately after a meal to enhance gastrointestinal tolerance. The film-coated tablet must be swallowed whole and must not be crushed, chewed, or divided.

A critical administration instruction is the separation of timing from other products. Fynal-OZ should not be taken within two hours of consuming products containing multivalent cations, such as iron, zinc, or antacids, to ensure adequate drug absorption.

Dosing Adjustments and Schedules

The standard regimen is one tablet per dose, twice daily. However, a high-level usage rule dictates that dose adjustment is required for patients who present with renal impairment, as the Levofloxacin component is primarily cleared through the kidneys.

This structured administration protocol, characterized by its fixed oral frequency and specific intake conditions, aligns the treatment with typical clinical patterns for acute mixed infections (consistent with patterns seen in related FDCs).

Instruction Classifications (High-Level)

Research Evidence / Overview of Studies for Fynal-OZ

This overview describes the research that has been studied for the drug components and the combination, focusing only on what the studies explored and what was observed, without making claims about effectiveness or clinical outcomes.

Evidence for Use in Mixed Gastrointestinal and Abdominal Infections

The combination of Levofloxacin and Ornidazole has been studied in the context of infections that frequently involve both aerobic (oxygen-requiring) bacteria and anaerobic organisms or protozoal organisms, which is a common scenario in conditions involving periods of heightened symptoms in the gut. Research efforts have explored the use of this combination in cases of diarrhea and dysentery and gynecological/pelvic infections. Randomized Controlled Trials (RCTs) and Systematic Reviews have monitored outcomes related to microbiological eradication, which measures the clearance of the pathogen from the body, and clinical success, which is used in research exploring how symptoms change over time in the observed populations.

Findings describe patterns observed in the studies related to the rate of pathogen clearance and patient-reported outcomes describing perceived discomfort during the short-term treatment period. Research describes the use of combination therapies to cover a broader antibiotic spectrum, which is relevant when the exact mix of infecting organisms is not known. The comparative evidence is lacking to fully clarify the clinical role of this specific fixed combination relative to other combination regimens or single agents for all types of mixed infections.

Evidence for Use in Targeted Systemic Infections

Research has extensively evaluated the Levofloxacin component, a type of fluoroquinolone, in populations with specific bacterial infections in adults. These are conditions associated with acute or disruptive episodes, such as pneumonia, certain urinary tract infections (UTIs), and sinusitis. Studies in these areas primarily focus on the single-agent activity of Levofloxacin, tracking outcomes related to time to clinical stability and the clearance of aerobic bacteria.

Trials data show patterns related to microbiological clearance and measurements related to clinical cure in organisms found to be susceptible to the Levofloxacin component. For these targeted systemic infections, much of the data regarding the use of the fixed combination (FDC) appears to be inferred from the established body of work on Levofloxacin alone. The evidence is limited when isolating the specific contribution of the Ornidazole component in systemic infections where there is no confirmed presence of protozoa or anaerobic bacteria.

Common questions about Fynal-OZ (FAQ)

Q: Who should not take Fynal-OZ (contraindications and ineligible groups)?

Regulatory documents indicate that Fynal-OZ is contraindicated in cases of known hypersensitivity to any quinolone or nitroimidazole drug. It is also listed as non-eligible for those with a history of Fluoroquinolone-associated tendon disorders, epilepsy, or Myasthenia Gravis. Official guidance states this medicine is also contraindicated for children, growing adolescents, pregnant women, and breast-feeding women.

Q: What are the common side effects of Fynal-OZ?

Official product information, based on the clinical data for the Levofloxacin component, identifies several reactions as common. The most frequently documented side effects include nausea, headache, diarrhea, insomnia, and dizziness. Regulatory documents include a general caution that all medicines may be associated with potential side effects.

Q: Why is it important to separate the timing of Fynal-OZ from antacids, iron, or zinc supplements?

The official product information states that Fynal-OZ should not be taken within two hours of consuming products that contain multivalent cations, such as certain antacids or supplements with iron or zinc. This separation is required because these cations can cause a chemical process called chelation. Chelation can reduce the absorption of the Levofloxacin component, potentially lowering the drug’s exposure and effectiveness.

Q: What should I do if I miss a dose of Fynal-OZ?

Official sources typically state that a missed dose may be taken as soon as it is remembered. However, if the time is almost near the next scheduled dose, the guidance is that the missed dose should be skipped entirely. The regular dosing schedule should then be continued, and it is advised not to take a double dose to try and make up for a missed one.

How to Store and Dispose of Fynal-OZ?

This section describes the mandatory official requirements for storing and discarding Fynal-OZ (Levofloxacin/Ornidazole) tablets.

Official Storage Conditions

Fynal-OZ must be stored below 30°C and must be protected from moisture and direct sunlight.

To preserve the medication's integrity, it must be kept in its original container and maintained tightly closed.

Safety and Disposal

It is mandatory to store the medicine out of the reach of children and pets to prevent accidental ingestion.

Any unused or expired Fynal-OZ tablets must be disposed of in accordance with local requirements and should not be flushed down the toilet.